Chen YY - Search Results

1

Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.

Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M, Tseng CH, Chen YY. Lin MY, et al. Among authors: chen yy. J Exp Med. 2024 Jun 3;221(6):e20221988. doi: 10.1084/jem.20221988. Epub 2024 Apr 12. J Exp Med. 2024. PMID: 38607370

2

Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells.

Ede C, Chen X, Lin MY, Chen YY. Ede C, et al. Among authors: chen yy, chen x. ACS Synth Biol. 2016 May 20;5(5):395-404. doi: 10.1021/acssynbio.5b00266. Epub 2016 Mar 1. ACS Synth Biol. 2016. PMID: 26883397 Free PMC article.

3

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. Zah E, et al. Among authors: chen yy. Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8. Cancer Immunol Res. 2016. PMID: 27059623 Free PMC article.

4

TGF-β-responsive CAR-T cells promote anti-tumor immune function.

Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. Hou AJ, et al. Among authors: chen yy. Bioeng Transl Med. 2018 Jul 27;3(2):75-86. doi: 10.1002/btm2.10097. eCollection 2018 May. Bioeng Transl Med. 2018. PMID: 30065964 Free PMC article.

5

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.

Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Zah E, et al. Among authors: chen yy. Nat Commun. 2020 May 8;11(1):2283. doi: 10.1038/s41467-020-16160-5. Nat Commun. 2020. PMID: 32385241 Free PMC article.

6

Engineering CAR-T Cells for Next-Generation Cancer Therapy.

Hong M, Clubb JD, Chen YY. Hong M, et al. Among authors: chen yy. Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30. Cancer Cell. 2020. PMID: 32735779 Free article. Review.

7

Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy.

Shih RM, Chen YY. Shih RM, et al. Among authors: chen yy. Cancer Immunol Res. 2022 Jan;10(1):6-11. doi: 10.1158/2326-6066.CIR-21-0769. Cancer Immunol Res. 2022. PMID: 34983828 Review.

8

Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.

Chen X, Chen LC, Khericha M, Meng X, Salvestrini E, Shafer A, Iyer N, Alag AS, Ding Y, Nicolaou DM, Chen YY. Chen X, et al. Among authors: chen yy, chen lc. Cancer Immunol Res. 2023 Feb 3;11(2):150-163. doi: 10.1158/2326-6066.CIR-22-0504. Cancer Immunol Res. 2023. PMID: 36409926 Free PMC article.

9

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.

Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. Larson SM, et al. Among authors: chen yy, chen jm. Cancer Discov. 2023 Mar 1;13(3):580-597. doi: 10.1158/2159-8290.CD-22-0964. Cancer Discov. 2023. PMID: 36416874 Free PMC article.

10

Extracellular Domains of CAR Reprogram T-Cell Metabolism Without Antigen Stimulation.

Lakhani A, Chen X, Chen LC, Khericha M, Chen YY, Park JO. Lakhani A, et al. Among authors: chen yy, chen lc, chen x. bioRxiv [Preprint]. 2023 Apr 4:2023.04.03.533021. doi: 10.1101/2023.04.03.533021. bioRxiv. 2023. PMID: 37066394 Free PMC article. Updated. Preprint.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,142 results

Search Page